Gene Therapy Reimbursement Strategies for Vision Restoration

Gene therapy reimbursement in the Netherlands has demonstrated clear clinical value since the 2021 conditional access agreement for voretigene neparvovec (Luxturna®). Five years of structured real-world use confirmed that carefully designed protocols successfully selected appropriate patients with biallelic RPE65 mutations and delivered meaningful vision improvement in half of the 26 individuals treated.

Vision Gains Translate into Daily Independence

Patients who regained visual function reported striking increases in independence and self-confidence during routine activities. These outcomes validate the effectiveness of tightly managed access programs for ultra-rare retinal disorders.

The Zorginstituut Nederland’s evaluation drew on three iterative consultation rounds involving clinicians, patient organisations, insurers and the institute itself. By limiting treatment to specialised centres, maintaining a national indication committee and operating a central registry, the programme ensured consistent adherence to eligibility criteria and systematic data collection.

Unilateral Dosing Cuts Costs While Protecting Safety

A 2022 protocol shift toward initial unilateral treatment frequently made second-eye injection unnecessary. This change preserved clinical benefit, improved patient safety and reduced overall expenditure by approximately 50 %, strengthening the economic case for gene therapy reimbursement.

Evidence-Based Foundation for 2028 Policy Review

Documented vision gains and successful unilateral dosing now supply concrete parameters for value-based payment models. The Zorginstituut has already scheduled a multi-stakeholder reassessment in 2028 to incorporate longer-term outcomes and prepare for the next wave of retinal gene therapies, ensuring gene therapy reimbursement frameworks remain both clinically sound and financially sustainable.